Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter

Business Practice

Business & Regulation Digital Technologies

On Cloud Nine?

| Maryam Mahdi | 3 min read

What difference can cloud-based systems make to data management?

Business & Regulation Digital Technologies

Three Questions on Data Management in Pharma

| Maryam Mahdi | 4 min read

Data management can be difficult but the right systems can help pharma manage the vast volumes of data it amasses.

Business & Regulation Digital Technologies

Digital Transformation: Veeva la Revolution!

| Maryam Mahdi | 4 min read

What difference will decentralized trials make to the future of clinical trials?

Business & Regulation Business Practice

Inside the Global Village

| Kariem Abdellatif | 3 min read

What are the best locations for a pharma business to base entities when it comes to operating costs?

Business & Regulation COVID-19

Enter the Weird World of Anti-Vaxxers

| Stephanie Sutton | 3 min read

Why, oh why, is there so much nonsense and misinformation about COVID-19 vaccines?

Business & Regulation Business Practice

Roe v. Wade and the Future of Medical Abortions in the US

| Maryam Mahdi | 2 min read

How will pharma companies navigate America’s new abortion laws?

Business & Regulation Business Practice

Champions of Cell and Gene Therapy

| Angus Stewart | 7 min read

In our third C+G Champions installment, we ask industry leaders in the cell and gene field about accessibility for the many

Business & Regulation Standards & Regulation

Acting on the Drug Supply Chain Security Act

| Shabbir Imber Safdar | 8 min read

The US drug supply chain is not immune to counterfeits – but there’s a law for that. Here’s how it has been used so far.

Discovery & Development Drug Discovery

DNDi: Medicine Makers Without Borders

| Angus Stewart

The DNDi is doing incredible work across the world. In this digital feature, we explore a portion of these open science efforts.

Discovery & Development Drug Discovery

How We Came to Start the Open Synthesis Network

| Ben Perry | 4 min read

This is the story of how DNDi put forward a new model for collaborative, open science.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine